Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 19, 2019

SELL
$8.85 - $12.49 $8 - $12
-1 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$10.32 - $14.49 $10 - $14
1 New
1 $0
Q4 2018

Feb 14, 2019

SELL
$8.73 - $13.74 $8 - $13
-1 Closed
0 $0
Q4 2017

Mar 09, 2018

BUY
$35.44 - $63.76 $35 - $63
1
1 $0

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $781M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Marino, Stram & Associates LLC Portfolio

Follow Marino, Stram & Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marino, Stram & Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marino, Stram & Associates LLC with notifications on news.